

Product Datasheet

CD79A Antibody (IGA/515) [DyLight 755] NBP2-47839IR

Unit Size: 0.1 ml

Store at 4C in the dark.

www.novusbio.com



technical@novusbio.com

Protocols, Publications, Related Products, Reviews, Research Tools and Images at:
www.novusbio.com/NBP2-47839IR

Updated 10/26/2023 v.20.1

Earn rewards for product
reviews and publications.

Submit a publication at www.novusbio.com/publications

Submit a review at www.novusbio.com/reviews/destination/NBP2-47839IR



NBP2-47839IR

CD79A Antibody (IGA/515) [DyLight 755]

Product Information	
Unit Size	0.1 ml
Concentration	Please see the vial label for concentration. If unlisted please contact technical services.
Storage	Store at 4C in the dark.
Clonality	Monoclonal
Clone	IGA/515
Preservative	0.05% Sodium Azide
Isotype	IgG1 Kappa
Conjugate	DyLight 755
Purity	Protein A or G purified
Buffer	50mM Sodium Borate

Product Description	
Description	This conjugate is made on demand. Actual recovery may vary from the stated volume of this product. The volume will be greater than or equal to the unit size stated on the datasheet.
Host	Mouse
Gene ID	973
Gene Symbol	CD79A
Species	Human
Marker	B-Cell Marker
Specificity/Sensitivity	A disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulin constitute the B cell Ag receptor. CD79a first appears at pre B cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in some myelomas. It is not present in myeloid or T cell lines. Anti-CD79a is generally used to complement anti-CD20 especially for mature B-cell lymphomas after treatment with Rituximab (anti-CD20). This antibody will stain many of the same lymphomas as anti-CD20, but also is more likely to stain B-lymphoblastic lymphoma/leukemia than is anti-CD20. Anti-CD79a also stains more cases of plasma cell myeloma and occasionally some types of endothelial cells as well.
Immunogen	Recombinant full-length human CD79A protein
Notes	DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.

Product Application Details	
Applications	Flow Cytometry, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Immunohistochemistry-Paraffin, CyTOF-ready, Immunofluorescence
Recommended Dilutions	Flow Cytometry, Immunohistochemistry, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry-Paraffin, Immunofluorescence, CyTOF-ready



Application Notes

Optimal dilution of this antibody should be experimentally determined.





Novus Biologicals USA

10730 E. Briarwood Avenue
Centennial, CO 80112
USA
Phone: 303.730.1950
Toll Free: 1.888.506.6887
Fax: 303.730.1966
nb-customerservice@bio-techne.com

Bio-Techne Canada

21 Canmotor Ave
Toronto, ON M8Z 4E6
Canada
Phone: 905.827.6400
Toll Free: 855.668.8722
Fax: 905.827.6402
canada.inquires@bio-techne.com

Bio-Techne Ltd

19 Barton Lane
Abingdon Science Park
Abingdon, OX14 3NB, United Kingdom
Phone: (44) (0) 1235 529449
Free Phone: 0800 37 34 15
Fax: (44) (0) 1235 533420
info.EMEA@bio-techne.com

General Contact Information

www.novusbio.com
Technical Support: nb-technical@bio-techne.com
Orders: nb-customerservice@bio-techne.com
General: novus@novusbio.com

Products Related to NBP2-47839IR

NBP1-43319IR-0.5ml	Mouse IgG1 Kappa Isotype Control (P3.6.2.8.1) [DyLight 755]
NBP2-60209-50ug	Recombinant Human CD79A His Protein
7268-CT-100	CTLA-4 [Unconjugated]
9685-CD-050	CD79A [Unconjugated]

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NBP2-47839IR

Earn gift cards/discounts by submitting a publication using this product:
www.novusbio.com/publications

